Combo Trials With Merck, Bristol Highlight Lilly’s Focus On Oncology Going Forward
This article was originally published in The Pink Sheet Daily
Executive Summary
Combo trials with Opdivo and Keytruda may help Lilly accelerate its move into cancer immunotherapy. Heading out of its patent cliff, the pharma is focused mainly on cancer, diabetes and neurology.